Trial results for the PRISM (Promoting Resilience in Stress Management) intervention for women with Breast Cancer were posted on ClinicalTrials.gov on 2025-10-14, indicating feasibility in 33 participants and a statistically significant mean improvement in resilience of 3.3 (p=0.0089).
Background
The PRISM intervention is an evidence-based program designed to build resilience by bolstering positive psychological tools, known as resilience resources. These resources include stress management, goal-setting, and positive reframing. The program was initially developed in adolescent and young adult oncology. Previous studies have shown PRISM to be successfully administered remotely, improving resilience, psychological distress, hope, and quality of life among adult caregivers. For individuals facing a diagnosis like breast cancer, psychological support and resilience-building interventions are crucial for managing the emotional and mental health challenges associated with their condition.
Trial design
This completed study, identified as Phase NA, enrolled 43 participants diagnosed with Breast Cancer. The intervention studied was the PRISM (Promoting Resilience in Stress Management) program, which utilizes centrally administered skills-based coaching. The trial aimed to assess the feasibility, acceptability, and impact of this resilience-building intervention in women with breast cancer. The study was a single-arm design, with all participants receiving the PRISM intervention.
Key results
The trial results focused on the feasibility and acceptability of the PRISM intervention, alongside its impact on resilience and post-traumatic growth:
- Feasibility of PRISM: The intervention demonstrated feasibility, with 33 participants and an additional 10 participants reported under this outcome.
- Acceptability, Appropriateness, and Feasibility: Participants rated these aspects highly, with mean scores of 4.5 (Standard Deviation 0.7), 4.5 (Standard Deviation 0.8), and 4.6 (Standard Deviation 0.5) on a scale.
- Resilience: Mean resilience scores were 28.5 (Standard Deviation 7.0) and 31.8 (Standard Deviation 5.6). A paired t-test showed a statistically significant mean difference in final values of 3.3 (95.0% CI: 0.9 to 5.8), with a p-value of 0.0089, indicating an increase in resilience.
- Overall Post-Traumatic Growth Inventory: Mean scores were 57.4 (Standard Deviation 28.7) and 67.8 (Standard Deviation 28.6). A paired t-test revealed a statistically significant mean difference in final values of 10.4 (95.0% CI: 2.0 to 18.8), with a p-value of 0.0169, suggesting an increase in overall post-traumatic growth.
- Post-Traumatic Growth Inventory: Personal Strength Sub-scale: Mean scores were 10.9 (Standard Deviation 6.0) and 13.2 (Standard Deviation 6.1). A paired t-test indicated a statistically significant mean difference in final values of 2.4 (95.0% CI: 0.5 to 4.3), with a p-value of 0.0162, showing an increase in personal strength.
- Post-Traumatic Growth Inventory: New Possibilities Sub-scale: A mean score of 11 (Standard Deviation 6.9) was reported. A paired t-test showed a statistically significant mean difference in final values of 3.4 (95.0% CI: 0.7 to 6.1), with a p-value of 0.0144.
What this means
The posted results suggest that the PRISM intervention is a feasible and acceptable program for women with breast cancer. The statistically significant improvements observed in resilience, overall post-traumatic growth, and specific sub-scales like personal strength and new possibilities indicate that this skills-based coaching program can positively impact the psychological well-being of patients. These findings support the potential integration of resilience-building interventions into supportive care for individuals undergoing breast cancer treatment, offering a valuable tool to enhance coping mechanisms and foster positive psychological adaptation.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06133348, titled "Promoting Resilience in Women With Breast Cancer", were posted on 2025-10-14 on clinicaltrials.gov.